Sep 15, 2026•3 min read
Addpharma speeds up reformulated Entresto candidate AD-118 for heart failure and hypertension
Addpharma, a Yuhan subsidiary, has received approval for a Phase 1 follow‑up trial of its AD-118 reformulation, targeting the post‑patent market for Entresto.